Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

EHA 2021 | State-of-the-art CAR-T therapy for B-ALL

Name: State-of-the-art CAR-T therapy for B-ALL
Uploaded: 2021-06-08T00:00:00Z
Duration: 32 s
Description: Daniel W. Lee, MD, University of Virginia, Charlottesville, VA, comments on state-of-the-art therapies for B-cell acute lymphoblastic leukemia (B-ALL), highlighting the findings of the ZUMA-4 trial (NCT02625480). This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

Daniel Lee • 8 Jun 2021

EHA 2021

Acute Lymphoblastic Leukemia Leukemia Brexucabtagene autoleucel CAR-T

ZUMA-4

Daniel W. Lee, MD, University of Virginia, Charlottesville, VA, comments on state-of-the-art therapies for B-cell acute lymphoblastic leukemia (B-ALL), highlighting the findings of the ZUMA-4 trial (NCT02625480). This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

Disclosures

Daniel W. Lee, MD, has participated in a consultancy role for Harpoon Therapeutics; has participated in an external advisory board for Amgen and Juno/Celgene/BMS; has received institutional research funding from Kite Pharma/Gilead; and is the spouse of an employee of Karyopharm Therapeutics.